{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:18:58Z","timestamp":1789989538634,"version":"4.0.1"},"reference-count":11,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Long\u2010term data of chronic lymphocytic leukemia (CLL) patients with favorable risk who were treated with fludarabine, cyclophosphamide, and rituximab (FCR) within clinical trials show good efficacy. We here report long\u2010term data collected within the GCLLSG registry. Altogether, 417 CLL patients who received first\u2010line treatment with FCR were analyzed, of which 293 (70.3%) were treated outside of clinical trials. The median observation time from first\u2010line was 95.8 (interquartile range 58.7\u2013126.8) months. Focusing on data of 194 (46.5%) patients who received FCR first\u2010line treatment after 2013 (start of data collection within GCLLSG registry), responses were documented in 85% of the patients, non\u2010responses in 15%, and for 3.6% the assessment was missing. Median event\u2010free survival (EFS, time until disease progression, subsequent treatment, or death) was 60.2\u2009months with a 5\u2010year EFS\u2010rate of 50.6%. Patients with higher\u2010risk disease, characterized by unmutated IGHV (<jats:italic>N<\/jats:italic>\u2009=\u200978), had a median EFS of 45.4\u2009months with a 5\u2010year EFS rate of 36.3%, while the median EFS was 77.5\u2009months with a 5\u2010year EFS rate of 60.3% in patients with mutated IGHV (<jats:italic>N<\/jats:italic>\u2009=\u200940). Median overall survival was not reached with a 5\u2010year survival rate of 92.7%. In summary, first\u2010line FCR was associated with long EFS, especially in patients exhibiting a mutated IGHV status.<\/jats:p>","DOI":"10.1111\/ejh.14220","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T05:12:35Z","timestamp":1714626755000},"page":"235-241","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Fludarabine, cyclophosphamide, and rituximab as first\u2010line treatment in patients with chronic lymphocytic leukemia: A long\u2010term analysis of the German CLL Study Group (GCLLSG) registry"],"prefix":"10.1111","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9559-8575","authenticated-orcid":false,"given":"Nadine","family":"Kutsch","sequence":"first","affiliation":[{"name":"Department I of Internal Medicine Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne  Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Giza","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne  Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Robrecht","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne  Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina","family":"Stumpf","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne  Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anno","family":"Federhen","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne  Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Stoltefu\u00df","sequence":"additional","affiliation":[{"name":"Evangelisches Krankenhaus Hamm  Hamm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Vehling\u2010Kaiser","sequence":"additional","affiliation":[{"name":"\u00dcBAG MVZ Dr. Vehling\u2010Kaiser GmbH  Landshut Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Koenigsmann","sequence":"additional","affiliation":[{"name":"Onkologisches Ambulanzzentrum Hannover"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Tausch","sequence":"additional","affiliation":[{"name":"Division of CLL, Department III of Internal Medicine University Hospital Ulm  Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Schneider","sequence":"additional","affiliation":[{"name":"Division of CLL, Department III of Internal Medicine University Hospital Ulm  Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[{"name":"Division of CLL, Department III of Internal Medicine University Hospital Ulm  Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Illmer","sequence":"additional","affiliation":[{"name":"Gemeinschaftspraxis H\u00e4matologie\u2010Onkologie  Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Schlag","sequence":"additional","affiliation":[{"name":"H\u00e4matologisch\u2010Onkologische Schwerpunktpraxis W\u00fcrzburg  W\u00fcrzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"D\u00f6rfel","sequence":"additional","affiliation":[{"name":"Onkozentrum Dresden Freiberg  Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gaska","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr H\u00e4matologie und Onkologie, Br\u00fcderkrankenhaus St. Josef  Paderborn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kiehl","sequence":"additional","affiliation":[{"name":"Medizinische Klinik I, Klinikum Frankfurt\/Oder  Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"M\u00fcller\u2010Hagen","sequence":"additional","affiliation":[{"name":"Praxis f\u00fcr H\u00e4matologie und Onkologie in Hamburg  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enno","family":"Moorahrend","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr H\u00e4matologie und Onkologie MVZ Porta Westfalica  Porta Westfalica Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Linde","sequence":"additional","affiliation":[{"name":"MVZ f\u00fcr Blut und Krebserkrankungen Potsdam  Potsdam Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Schlenska\u2010Lange","sequence":"additional","affiliation":[{"name":"Barmherzige Br\u00fcder Krankenhaus Regensburg  Regensburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5873-4603","authenticated-orcid":false,"given":"Julia","family":"von Tresckow","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Essen  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Fischer","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne  Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Eichhorst","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne  Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne  Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Fink","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne  Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014960"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00144-4"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020158"},{"key":"e_1_2_6_6_1","article-title":"Long term follow\u2010up data and health\u2010related quality of life in frontline therapy of fit patients treated with FCR versus BR (CLL10 trial of the GCLLSG)","volume":"4","author":"Kutsch N","year":"2020","journal-title":"Hema"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.5398"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.957203"},{"key":"e_1_2_6_10_1","volume-title":"Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma","author":"Facts: SCS"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2856"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004922"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T04:25:52Z","timestamp":1719980752000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1111\/ejh.14220"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14220","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"2024-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}